C+
Overall grade
C
Financial quality
The sleeper story is NTLA's financial dependency on nex-z timing - with mid-2027 runway and $111M quarterly burn, any significant delay pushes them into financing territory during a crisis. Management's repeated emphasis on 'comprehensive analysis' signals this hold lasting months, not weeks. The obvious headline is the patient death and clinical hold, but the real constraint is FDA's timeline for restart requirements, which is completely outside management's control. Most revealing quote: 'We can only speculate, which we're not going to do' - unprecedented admission of mechanistic uncertainty. My view changes if the FDA clinical hold letter shows a clear, time-bounded path to restart rather than open-ended requirements.
The 30-second version
- THE SLEEPER STORY: Clinical hold reveals NTLA's financial dependency on nex-z timing
- Patient death forces milestone guidance withdrawal but lonvo-z timeline unchanged
- Less than 1% liver toxicity rate across 650+ patients, but management can't explain mechanism
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Cash & equivalents | $630.5M (Q2 2025) | $669.9M (Q3 2025) |
| ATM utilization | Opportunistic use only | $115M raised in Q3 |
| Collaboration revenue | $14.2M (Q2 2025) | $13.8M (Q3 2025) |
| R&D expenses | $97.0M (Q2 2025) | $94.7M (Q3 2025) |
| Net loss | Not specified for Q2 | $101.3M (Q3 2025) |
| MAGNITUDE enrollment | 550+ patients by year-end (guidance) | 650+ patients enrolled |
| MAGNITUDE-2 enrollment | Starting in Q1 2025 | 47 patients enrolled before hold |
| HAELO enrollment | Complete in Q3 2025 | Completed in September |
Accountability tracked
6 new promises made4 narrative shifts flagged7 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →